And I suppose a person of your intelligence assumes that directors with the back-round and education this person has should work for free………right……..he has 5,000,000 shares and sells half big deal… Do you work for free????
Erkki Ruoslahti is a cancer researcher at the Sanford-Burnham Medical Research Institute and University of California Santa Barbara. Ruoslahti made seminal contributions to biology of extracellular matrix and its receptors. He introduced the concept of vascular zip codes (the idea that each tissue bears molecular sigantures that can be targeted by affinity ligands) and used in vivo peptide phage display to prove the concept and develop numerous tumor homing peptides. His group has developed of a novel class of cell- and tissue penetrating peptides that can be used for biological delivery of drugs and nanoparticles to extravascular spece in tissues. When exposed at the C-terminus of the peptide, such C-end Rule (CendR, pronounced "sender") peptides bind to neuropilin-1 and cause vascular leakage and tissue penetration. iRGD is a pan-tumor penetrating CendR peptide that can be used for tumor delivery of conjugated and combination delivery of various payloads (drugs, imaging agents).  Awards and honors
* American Association for Cancer Research - G.H.A. Clowes Award * Robert J. and Claire Pasarow Foundation Medical Research Award * Jacobaeus International Prize * Jubilee Award given by the British Biomedical Society * Nobel Fellow at the Karolinska Institute in Stockholm (1995) * Honorary Doctorate from the University of Lund * Knight of the Order of the White Rose of Finland * Japan Prize in Cell Biology (2005)
* Member of o U.S. National Academy of Sciences o Institute of Medicine o American Academy of Arts and Sciences o European Molecular Biology Organization